Robert B. Belshe

22.4k total citations · 3 hit papers
256 papers, 16.7k citations indexed

About

Robert B. Belshe is a scholar working on Epidemiology, Infectious Diseases and Virology. According to data from OpenAlex, Robert B. Belshe has authored 256 papers receiving a total of 16.7k indexed citations (citations by other indexed papers that have themselves been cited), including 194 papers in Epidemiology, 68 papers in Infectious Diseases and 67 papers in Virology. Recurrent topics in Robert B. Belshe's work include Respiratory viral infections research (115 papers), Influenza Virus Research Studies (106 papers) and HIV Research and Treatment (44 papers). Robert B. Belshe is often cited by papers focused on Respiratory viral infections research (115 papers), Influenza Virus Research Studies (106 papers) and HIV Research and Treatment (44 papers). Robert B. Belshe collaborates with scholars based in United States, France and United Kingdom. Robert B. Belshe's co-authors include Frances K. Newman, Mark Wolff, Geoffrey J. Gorse, David I. Bernstein, William C. Gruber, Sharon E. Frey, Paul M. Mendelman, Frederick G. Hayden, Maurice A. Mufson and Alan Hay and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Robert B. Belshe

254 papers receiving 15.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

1998 697 citations Robert B. Belshe, Paul M. Mendelman et al. New England Journal of Medicine profile →
Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young Children

2007 611 citations Robert B. Belshe, Kathryn M. Edwards et al. New England Journal of Medicine profile →
Efficacy Results of a Trial of a Herpes Simplex Vaccine

2012 376 citations Robert B. Belshe, Peter A. Leone et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Robert B. Belshe

Since Specialization

Citations

This map shows the geographic impact of Robert B. Belshe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert B. Belshe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert B. Belshe more than expected).

Fields of papers citing papers by Robert B. Belshe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert B. Belshe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert B. Belshe. The network helps show where Robert B. Belshe may publish in the future.

Co-authorship network of co-authors of Robert B. Belshe

This figure shows the co-authorship network connecting the top 25 collaborators of Robert B. Belshe. A scholar is included among the top collaborators of Robert B. Belshe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert B. Belshe. Robert B. Belshe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vaccine and Treatment Evaluation Units: A Historical Perspective 2025 ·Clinical Infectious Diseases ·Robert B. Belshe, David I. Bernstein, Kathryn M. Edwards, Sharon E. Frey, Wendy A. Keitel, Myron Levine, John J. Treanor, Peter F. Wright	0
2	Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines 2022 ·The Journal of Infectious Diseases ·(unknown), (unknown), Tamara P. Blevins, Natalia Cheshenko, Wei Gao, Kathryn Anastos, Robert B. Belshe, Betsy C. Herold	10
3	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial 2019 ·PLoS ONE ·Cristina Carter, Katherine V. Houser, Galina V. Yamshchikov, Abbie R. Bellamy, Jeanine May, Mary E. Enama, Uzma Sarwar, Brenda Larkin, Robert T. Bailer, Richard A. Koup, Grace Chen, Shital M. Patel, Patricia Winokur, Robert B. Belshe, Cornelia L. Dekker, Barney S. Graham, Julie E. Ledgerwood, (unknown)	16
4	Better Neutralization of Herpes Simplex Virus Type 1 (HSV-1) Than HSV-2 by Antibody From Recipients of GlaxoSmithKline HSV-2 Glycoprotein D2 Subunit Vaccine 2014 ·The Journal of Infectious Diseases ·Sita Awasthi, Robert B. Belshe, Harvey M. Friedman	54
5	Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario 2013 ·Vaccine ·Sharon E. Frey, Patricia Winokur, Robert A. Salata, Samer S. El‐Kamary, Christine B. Turley, Emmanuel B. Walter, Christine M. Hay, Frances K. Newman, Heather R. Hill, Ying Zhang, Paul Chaplin, Magdalena Tary‐Lehmann, Robert B. Belshe	50
6	Efficacy Results of a Trial of a Herpes Simplex Vaccine breakdown → 2012 ·New England Journal of Medicine ·Robert B. Belshe, Peter A. Leone, David I. Bernstein, Anna Wald, Myron J. Levin, Jack T. Stapleton, Iris Gorfinkel, Rhoda Morrow, Marian Ewell, Abbie Stokes‐Riner, Gary Dubin, Thomas C. Heineman, Joann Schulte, Carolyn Deal	376
7	Age-Associated Decrease in TLR Function in Primary Human Dendritic Cells Predicts Influenza Vaccine Response 2010 ·The Journal of Immunology ·Alexander Panda, Feng Qian, Subhasis Mohanty, David van Duin, Frances K. Newman, Lin Zhang, Shu Chen, Virginia Towle, Robert B. Belshe, Erol Fikrig, Heather Allore, Ruth R. Montgomery, Albert C. Shaw	418
8	Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine 2010 ·Vaccine ·Chin‐Fen Yang, Robert B. Belshe, George Kemble, (unknown), Dan Ye, (unknown), (unknown), Christopher S. Ambrose, (unknown), Robert Walker	5
9	The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults 2010 ·Influenza and Other Respiratory Viruses ·Christopher S. Ambrose, Myron J. Levin, Robert B. Belshe	140
10	Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults 2008 ·The Journal of Infectious Diseases ·David I. Bernstein, Kathryn M. Edwards, Cornelia L. Dekker, Robert B. Belshe, H. Keipp Talbot, Irene Graham, Diana L. Noah, (unknown), Heather Hill	176
11	Safety, Efficacy, and Effectiveness of Live, Attenuated, Cold‐Adapted Influenza Vaccine in an Indicated Population Aged 5–49 Years 2004 ·Clinical Infectious Diseases ·Robert B. Belshe, Kristin L. Nichol, (unknown), Henry R. Shinefield, Julie Cordova, Robert Walker, Colin Hessel, Iksung Cho, Paul M. Mendelman	78
12	Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine 2004 ·Expert Review of Vaccines ·Robert B. Belshe, (unknown), Robert Walker, Jeffrey J. Stoddard, Paul M. Mendelman	111
13	Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent 2003 ·Immunology and Allergy Clinics of North America ·Robert B. Belshe, Paul M. Mendelman	17
14	Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children 2001 ·The Pediatric Infectious Disease Journal ·James C. King, Patricia Fast, Kenneth M. Zangwill, Geoffrey A. Weinberg, Mark Wolff, Lihan Yan, (unknown), Robert B. Belshe, Andrea Kovacs, Jaime G. Deville, Marie T. Jelonek	67
15	HIV Type 1 Vaccine-Induced T Cell Memory and Cytotoxic T Lymphocyte Responses in HIV Type 1-Uninfected Volunteers 2001 ·AIDS Research and Human Retroviruses ·Geoffrey J. Gorse, Gira Patel, Robert B. Belshe	20
16	A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection 2000 ·AIDS Research and Human Retroviruses ·M. Juliana McElrath, Lawrence Corey, David C. Montefiori, Mark Wolff, (unknown), Michael C. Keefer, Robert B. Belshe	45
17	A Review of Attenuation of Influenza Viruses by Genetic Manipulation 1995 ·American Journal of Respiratory and Critical Care Medicine ·Robert B. Belshe	18
18	Determinants Of Antibody Response After Recombinant Gp160 Boosting In Vaccinia-Naive Volunteers Primed With Gp160-Recombinant Vaccinia Virus 1994 ·The Journal of Infectious Diseases ·Barney S. Graham, Geoffrey J. Gorse, David H. Schwartz, M. C. Keefer, M. Juliana McElrath, Thomas J. Matthews, Peter F. Wright, Robert B. Belshe, M L Clements, Raphael Dolin, Lawrence Corey, Dani P. Bolognesi, D Stablein, Joy Esterlitz, Shiu-Lok Hu, Gale Smith	29
19	Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans 1994 ·AIDS Research and Human Retroviruses ·Michael C. Keefer, Barney S. Graham, Robert B. Belshe, David H. Schwartz, Lawrence Corey, Dani P. Bolognesi, Donald M. Stablein, David C. Montefiori, (unknown), M L Clements, Geoffrey J. Gorse, Peter F. Wright, Thomas J. Matthews, Gale Smith, Dale N. Lawrence, Raphael Dolin	46
20	Superiority of Live Attenuated Compared with Inactivated Influenza A Virus Vaccines in Older, Chronically III Adults 1991 ·CHEST Journal ·Geoffrey J. Gorse, Robert B. Belshe, (unknown)	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact